Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug699 | CH505TF gp120 Wiki | 1.00 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This study will evaluate the safety and immune response in healthy HIV-exposed and uninfected infants to the protein vaccine, CH505TF gp120, adjuvanted with GLA-SE.
Description: Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017
Measure: Local reactogenicity signs and symptoms Time: Measured through week 55Description: Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017
Measure: Systemic reactogenicity signs and symptoms Time: Measured through week 55Description: Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017
Measure: Frequency of adverse events (AEs) Time: Measured through week 106Description: Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017
Measure: Frequency of serious adverse events (SAEs) Time: Measured through week 106Description: Measured by Binding antibody multiplex assay (BAMA)
Measure: Magnitude of HIV-1 specific serum IgG binding antibodies Time: Measured at week 56Description: Measured by flow cytometry
Measure: Quantification of peripheral B cells capable of binding HIV-1 Env gp120, the CD4 binding site (including differential binding to the IΔ371 mutant) and the V1V2 binding site Time: Measured at week 18Description: Measured by flow cytometry
Measure: Quantification of peripheral B cells capable of binding HIV-1 Env gp120, the CD4 binding site (including differential binding to the IΔ371 mutant) and the V1V2 binding site Time: Measured at week 56Description: Measured by flow cytometry
Measure: Phenotypic characterization of peripheral B cells capable of binding HIV-1 Env gp120, the CD4 binding site (including differential binding to the IΔ371 mutant) and the V1V2 binding site Time: Measured at week 18Description: Measured by flow cytometry
Measure: Phenotypic characterization of peripheral B cells capable of binding HIV-1 Env gp120, the CD4 binding site (including differential binding to the IΔ371 mutant) and the V1V2 binding site Time: Measured at week 56Description: Measured by Pediatric Vaccine Multiplex Assay (PVMA)
Measure: EPI vaccine-specific antibody responses Time: Measured at week 56Description: Measured by TZM-bl assay
Measure: Magnitude of serum neutralization of vaccine-matched viral isolates, and viruses engineered to detect precursors of CD4 binding site and V1V2 antibodies Time: Measured at week 56Description: Measured by TZM-bl assay
Measure: Serum neutralization of vaccine-matched viral isolates, and viruses engineered to detect precursors of CD4 binding site and V1V2 antibodies Time: Measured at week 56Description: Measured by BAMA
Measure: Response rate of vaccine-elicited serum binding antibodies to FcR proteins Time: Measured at week 56Description: Measured by BAMA
Measure: Magnitude of vaccine-elicited serum binding antibodies to FcR proteins Time: Measured at week 56Description: Measured by flow cytometry and/or luciferase assays
Measure: Response rate of serum Antibody-dependent cellular cytotoxicity (ADCC) Time: Measured at week 56Description: Measured by flow cytometry and/or luciferase assays
Measure: Magnitude of serum Antibody-dependent cellular cytotoxicity (ADCC) Time: Measured at week 56Description: Measured by flow cytometry
Measure: Response rate of serum Antibody-dependent cellular phagocytosis (ADCP) Time: Measured at week 56Description: Measured by flow cytometry
Measure: Magnitude of serum Antibody-dependent cellular phagocytosis (ADCP) Time: Measured at week 56Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports